Study guide
5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
Key Takeaways Explain This Topic AI
A conventionally manufactured multiple-dose container may be used for up to 28 days after it is first entered, unless the labeling specifies otherwise.
A single-dose vial entered only in ISO Class 5 or cleaner air may be used for up to 12 hours after the first puncture, if its labeled storage conditions are maintained.
An opened single-dose ampule must not be stored for any time, and a vial whose septum has been removed, or an opened plastic luer-lock vial, is treated the same way.
A pharmacy bulk package must be entered only in an ISO Class 5 PEC and used according to its labeling. When the labeling gives both a stability time and a shorter in-use time, the shorter one applies.
The 12-hour allowance applies only when every entry is made in ISO Class 5 air; a single-dose container opened anywhere else is used for that preparation only and the remainder is discarded.
Last updated: September 2026
Container Closure Architecture & Antimicrobial Preservatives
Commercial pharmaceutical packaging systems differ fundamentally in their vulnerability to microbial ingress. The presence or absence of an antimicrobial preservative system dictates how long a container may be stored and repeatedly entered once the manufacturer seal is breached.
1. Multiple-Dose Containers (MDCs)
Definition : A container of sterile medication intended for parenteral administration that contains an antimicrobial preservative system (e.g., benzyl alcohol, methylparaben, phenol) validated to inhibit microbial proliferation over multiple entries.
The 28-Day Rule : Under USP <797>, once a conventionally manufactured MDC is first punctured or entered, it must not be used for more than 28 days , unless the manufacturer's labeling specifies otherwise.
Labeling Practice : Facilities write the date first opened and the resulting in-use date on the container. This is a CDC and accreditation expectation rather than USP <797> text.
Important
An MDC must be stored under manufacturer-specified conditions. If an MDC's manufacturer expiration date is shorter than 28 days, the container expires on the manufacturer date.
Single-Dose Containers (SDCs) and Vials
A Single-Dose Container (SDC) is designed for parenteral, ophthalmic, or otic administration in a single patient. SDCs lack antimicrobial preservatives . Once breached, any introduced bacteria or fungi can multiply rapidly.
Puncture and Storage Rules for SDC Vials
Entered only in ISO Class 5 Air : If a single-dose vial is entered or punctured only in ISO Class 5 or cleaner air, it may be used for up to 12 hours after the first puncture, as long as its labeled storage conditions are kept. USP's FAQ says the vial may be stored outside the PEC between entries, but every entry must be made inside ISO Class 5 air.
Entered in Worse than ISO Class 5 Air : The 12-hour allowance does not apply. The vial is used for the preparation at hand and the remainder is discarded. Under the immediate-use provision, leftover single-dose components are discarded when the preparation is complete.
Compromised Closures : A vial whose septum or metal ring has been removed, or an opened plastic luer-lock vial, is treated like an ampule and cannot be stored (USP FAQ).
Glass Ampules: Zero Storage Permitted
Glass ampules are single-dose containers without septa. Opening an ampule involves fracturing glass, exposing fluid directly to air:
Immediate Use Only : Once an ampule is opened, its contents must be drawn up immediately .
No Storage : Any unused fluid remaining in an ampule must be discarded immediately . It cannot be stored for 12 hours, even if maintained continuously within an ISO Class 5 laminar airflow hood.
Pharmacy Bulk Packages (PBPs)
A Pharmacy Bulk Package (PBP) is a container of a sterile preparation for parenteral use that contains many single doses. Common examples include large 2-liter bags of sterile water for injection, amino acid stock bottles, and large-volume concentrated electrolytes used in automated compounding devices (ACDs).
Operating Mandates for PBPs
ISO 5 Requirement : A PBP must be entered or punctured only within an ISO Class 5 PEC .
Transfer Protocol : The PBP is used exclusively to prepare sterile admixtures using a sterile transfer set or automated compounding device.
Beyond-Use Duration : PBPs are used according to the manufacturer's labeling. Some labeling gives a long stability time (for example, 14 days) and a shorter in-use time based on microbial risk (for example, 4 hours). USP's FAQ says the shorter time governs. The 2008 chapter's default of 6 hours is no longer in USP <797>.
Clinical Toxicities of Antimicrobial Preservatives
While antimicrobial preservatives inhibit microbial proliferation in multiple-dose containers, they present serious clinical and toxicological risks in specific patient populations:
1. Neonatal Gasping Syndrome (Benzyl Alcohol)
Benzyl alcohol is a common bacteriostatic preservative in multi-dose sodium chloride, sterile water, and heparin flushes. In neonates—particularly premature and low-birth-weight infants—immature hepatic alcohol dehydrogenase and glycine conjugation pathways fail to metabolize benzyl alcohol efficiently. The resulting toxic accumulation of benzoic acid produces gasping syndrome , characterized by severe metabolic acidosis, encephalopathy, respiratory failure with gasping respirations, renal impairment, and cardiovascular collapse.
Caution
Preservative-Free Mandate for Neonates : Medications and flush solutions for neonates (younger than 28 days or weighing less than 2.5 kg) must strictly be preservative-free. Never administer bacteriostatic solutions containing benzyl alcohol to neonatal patients.
2. Neuraxial Neurotoxicity (Intrathecal and Epidural Administration)
Administration of compounded medications into the cerebrospinal fluid (intrathecal) or epidural space directly exposes delicate neural tissue without blood-brain barrier protection. Preservatives such as benzyl alcohol, parabens, and phenol induce direct neurotoxic damage, chemical arachnoiditis, demyelination, and permanent paraplegia. All neuraxial compounded preparations must be formulated using certified preservative-free commercial components.
3. Lipid Injectable Emulsion and Propofol Hang-Time Limits
Lipid injectable emulsions (such as 10%, 20%, and 30% IVLE) and propofol lack bacteriostatic preservatives and possess a neutral-to-alkaline pH that supports rapid microbial proliferation:
Propofol Bottles/Vials : When spiked directly from the manufacturer vial, administration must be completed within 12 hours.
Propofol Syringes : Compounded or transferred into syringes, administration must be completed within 6 hours.
Intravenous Lipid Emulsions (IVLE) : When infused separately, the infusion hang time is strictly limited to 12 hours.
Total Nutrient Admixtures (3-in-1 TNAs) : Infusion hang time is permitted up to 24 hours because the amino acid and dextrose components provide buffer and hypertonic protection.